Blair William & CO Akebia Therapeutics, Inc. Transaction History

Blair William & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$0.72 - $2.93 $11,951 - $48,635	-16,599 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.26 - $3.34 $14,251 - $21,062	-6,306 Reduced 27.53%	16,599 $38,000
Q3 2021 Nov 12, 2021	SELL	$2.35 - $3.88 $9,536 - $15,745	-4,058 Reduced 15.05%	22,905 $66,000
Q1 2021 May 13, 2021	BUY	$2.92 - $5.06 $4,120 - $7,139	1,411 Added 5.52%	26,963 $91,000
Q4 2020 Feb 09, 2021	SELL	$2.22 - $3.78 $104,895 - $178,605	-47,250 Reduced 64.9%	25,552 $72,000
Q3 2020 Nov 06, 2020	BUY	$2.39 - $13.08 $22,112 - $121,016	9,252 Added 14.56%	72,802 $183,000
Q2 2020 Aug 12, 2020	SELL	$6.67 - $13.58 $8,290 - $16,879	-1,243 Reduced 1.92%	63,550 $863,000
Q4 2019 Feb 13, 2020	SELL	$3.16 - $6.73 $27,201 - $57,931	-8,608 Reduced 11.73%	64,793 $409,000
Q3 2019 Nov 12, 2019	SELL	$3.55 - $5.4 $7,100 - $10,800	-2,000 Reduced 2.65%	73,401 $288,000
Q1 2019 May 14, 2019	BUY	$5.41 - $8.73 $31,518 - $50,860	5,826 Added 8.37%	75,401 $618,000
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $375,009 - $636,611	69,575 New	69,575 $385,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $438M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.